Articles from Vaxxas

Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company advances its novel high-density microarray patch (HD-MAP) vaccine technology towards later stage clinical trials and commercialization.
By Vaxxas · Via Business Wire · February 5, 2025

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness Innovations, has approved the progression of a US$4.8 million (AU$7.2 million) program to develop heat-stable, dried-formulation mRNA vaccines delivered using Vaxxas’ needle-free high-density microarray patch (HD-MAP).
By Vaxxas · Via Business Wire · January 22, 2025

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a Concept Stage winner of the United States Biomedical Advanced Research and Development Authority’s (BARDA’s) $50 million Patch Forward Prize.
By Vaxxas · Via Business Wire · January 13, 2025

Vaxxas, a clinical-stage biotechnology company, has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the high-density microarray patch (HD-MAP), in the United States, Europe, Asia and Australia.
By Vaxxas · Via Business Wire · November 24, 2024

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that the United States National Institutes of Health (NIH) has granted the company a license to a next-generation vaccine antigen (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV).
By Vaxxas · Via Business Wire · October 28, 2024

Vaxxas today announced that it has initiated a multi-center Phase I clinical trial of a vaccine against pre-pandemic avian influenza strain H7N9, using the company’s high-density microarray patch (HD-MAP).
By Vaxxas · Via Business Wire · September 11, 2024

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, has published positive results from a human clinical trial involving its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch, instead of using traditional needle and syringe.
By Vaxxas · Via Business Wire · November 26, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced a publication in the journal Vaccine entitled “Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.”
By Vaxxas · Via Business Wire · October 18, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global charitable foundation, Wellcome, has made an award totaling US$3.67 million (AU$5.4 million / GB£2.84 million) to conduct IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch (HD-MAP) platform technology. The project is expected to be completed within two years.
By Vaxxas · Via Business Wire · August 23, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the opening of its first, state-of-the-art manufacturing facility in Brisbane, Queensland. The custom-built 5,500 square meter (60,000 square feet) Vaxxas Biomedical Facility will serve as the company’s global headquarters and support the scale-up of its operations to produce HD-MAP vaccines for future late-stage clinical trials and first commercial products.
By Vaxxas · Via Business Wire · June 18, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
By Vaxxas · Via Business Wire · June 5, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer. Dr. Chaiken joins Vaxxas following a 23-year career at Pfizer, bringing extensive experience designing and executing late-stage clinical trials and successfully launching new products in markets.
By Vaxxas · Via Business Wire · June 5, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of clinical trial data demonstrating the potential of Vaxxas’ high-density microarray patch (HD-MAP) to effectively deliver vaccine payloads when used either by trained professionals or individual self-administration. The data reported in Human Vaccines & Immunotherapeutics, demonstrated equivalency of observed human skin response and vaccine delivery potential when comparing administration by a trained professional versus participant patch self-administration.
By Vaxxas · Via Business Wire · March 30, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
By Vaxxas · Via Business Wire · February 9, 2023

CEPI, the Coalition for Epidemic Preparedness Innovations, and Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, have signed a partnership agreement to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology in a project that could end the need for frozen storage of mRNA vaccines. CEPI will provide up to USD4.3 million (AUD6.4 million) for preclinical testing of Vaxxas’ platform—a needle- free, high-density microarray patch (HD-MAP) to assess its stability, safety and immunogenicity and to evaluate its potential as a rapid-response technology for heat-stable, dried-formulation mRNA vaccines.
By Vaxxas · Via Business Wire · January 17, 2023

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced it has completed a financing round which raised US$23 million (A$34 million) in new funds. This investment round was led by existing investors OneVentures and UniQuest Pty Ltd. New investors include members of the Vaxxas Board of Directors, management team, and a number of individual investors.
By Vaxxas · Via Business Wire · December 5, 2022

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced another key addition to its executive leadership team with the appointment of Doug Cubbin as Chief Financial Officer. Doug joins Vaxxas as the company experiences significant growth and advances toward commercialization of its high-density microarray patch (HD-MAP) vaccine delivery technology.
By Vaxxas · Via Business Wire · December 1, 2022

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.
By Vaxxas · Via Business Wire · November 8, 2022

Vaxxas will receive an AU$8.2 million second round grant as part of the Australian Federal Government’s Modern Manufacturing Initiative (MMI) to support the manufacturing scale-up of its potentially game-changing technology that enables vaccines to be applied to the skin using a small patch.
By Vaxxas · Via Business Wire · September 20, 2022

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, is pleased to announce a key appointment to its executive leadership team that will strengthen the company’s engineering and manufacturing operations and support the company’s robust and accelerating growth. Scott Fry joins the company as Chief Operating Officer and will lead Engineering and Manufacturing activities at Vaxxas.
By Vaxxas · Via Business Wire · April 20, 2022

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, is pleased to announce a key appointment to its executive leadership team aimed at facilitating the company’s continued and accelerating growth. Dan Devine joins the company as Chief Business Officer and General Counsel. Dan will drive and facilitate the expansion of Vaxxas’ proprietary vaccine pipeline, support its existing and future industry and government partnerships, and help build out the company’s internal manufacturing and product development capabilities.
By Vaxxas · Via Business Wire · April 13, 2022

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that The University of Texas at Austin has granted Vaxxas an exclusive license to a next-generation SARS-CoV-2 spike subunit vaccine (HexaPro), for vaccination using a patch.
By Vaxxas · Via Business Wire · March 23, 2022

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that research demonstrating the potential of Vaxxas’ novel high-density microarray patch (HD-MAP) for vaccination against COVID-19 had been published in a manuscript posted to the preprint server BioRxiv. Using a novel SARS-CoV-2 spike subunit vaccine, this preclinical study of Vaxxas’ HD-MAP showed enhancement of immune response compared to vaccination by needle-and-syringe, including significantly enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery. Notably, complete protection from COVID-19 by a single dose skin patch delivery using HD-MAP was shown in a lethal virus challenge in a relevant COVID-19 animal model. Comparable protection against COVID-19 was not seen with the same vaccine when delivered by needle-and-syringe, even when the spike subunit vaccine formulation included appropriate adjuvantation. The research underlying the study was co-funded by Vaxxas and the Queensland Government and was performed in collaboration with researchers at the University of Queensland and Griffith University and led by principal investigator, David A. Muller, PhD, of the School of Chemistry and Molecular Biosciences at the University of Queensland.
By Vaxxas · Via Business Wire · June 2, 2021